HK1162665A1 - Prognosis and risk assessment in patients having suffered a stroke or a transient ischemic attack by determining the level of marker peptides - Google Patents

Prognosis and risk assessment in patients having suffered a stroke or a transient ischemic attack by determining the level of marker peptides

Info

Publication number
HK1162665A1
HK1162665A1 HK12102663.8A HK12102663A HK1162665A1 HK 1162665 A1 HK1162665 A1 HK 1162665A1 HK 12102663 A HK12102663 A HK 12102663A HK 1162665 A1 HK1162665 A1 HK 1162665A1
Authority
HK
Hong Kong
Prior art keywords
prognosis
suffered
patients
stroke
determining
Prior art date
Application number
HK12102663.8A
Other languages
English (en)
Chinese (zh)
Inventor
Andreas Bergmann
Nils Morgenthaler
Beat Mller
Original Assignee
有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 有限公司 filed Critical 有限公司
Publication of HK1162665A1 publication Critical patent/HK1162665A1/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
    • G01N21/76—Chemiluminescence; Bioluminescence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57527—Calcitonin gene related peptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57536—Endothelin, vasoactive intestinal contractor [VIC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/16—Oxytocins; Vasopressins; Related peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4737—C-reactive protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/585—Calcitonins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Plasma & Fusion (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
HK12102663.8A 2008-10-24 2012-03-16 Prognosis and risk assessment in patients having suffered a stroke or a transient ischemic attack by determining the level of marker peptides HK1162665A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08167512 2008-10-24
EP08168671 2008-11-07
PCT/EP2009/007738 WO2010046136A1 (en) 2008-10-24 2009-10-22 Prognosis and risk assessment in stroke patients by determining the level of marker peptides

Publications (1)

Publication Number Publication Date
HK1162665A1 true HK1162665A1 (en) 2012-08-31

Family

ID=41471029

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12102663.8A HK1162665A1 (en) 2008-10-24 2012-03-16 Prognosis and risk assessment in patients having suffered a stroke or a transient ischemic attack by determining the level of marker peptides

Country Status (7)

Country Link
US (2) US20110263821A1 (xx)
EP (1) EP2356450B1 (xx)
JP (2) JP5902479B2 (xx)
CN (1) CN102257386B (xx)
ES (1) ES2724478T3 (xx)
HK (1) HK1162665A1 (xx)
WO (1) WO2010046136A1 (xx)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10316583A1 (de) * 2003-04-10 2004-10-28 B.R.A.H.M.S Aktiengesellschaft Bestimmung eines midregionalen Proadrenomedullin-Teilpeptids in biologischen Flüssigkeiten zu diagnostischen Zwecken, sowie Immunoassays für die Durchführung einer solchen Bestimmung
JP2009536727A (ja) 2006-04-04 2009-10-15 シングレックス，インコーポレイテッド 高感度のマーカー分析および分子検出のための方法および組成物
US7838250B1 (en) 2006-04-04 2010-11-23 Singulex, Inc. Highly sensitive system and methods for analysis of troponin
ES2652027T3 (es) * 2006-10-26 2018-01-31 B.R.A.H.M.S. Gmbh Estratificación de riesgo del síndrome coronario agudo por medio de fragmentos / péptidos parciales de la provasopresina, en particular copeptina o neurofisina II
ES2724478T3 (es) 2008-10-24 2019-09-11 Brahms Gmbh Pronóstico y evaluación del riesgo en pacientes con accidente cerebrovascular determinando el nivel de péptidos marcadores
CA2751090A1 (en) * 2009-01-30 2010-08-05 Bio-Rad Innovations Method for the in vitro diagnosis of stroke
AU2010259022B2 (en) 2009-06-08 2016-05-12 Singulex, Inc. Highly sensitive biomarker panels
CN102702324B (zh) * 2011-09-15 2015-04-22 重庆业为基生物科技有限公司 人降钙素原b细胞表位肽段及其单克隆抗体的应用
KR101950561B1 (ko) * 2011-10-17 2019-02-20 에프. 호프만-라 로슈 아게 트로포닌 및 ｂｎｐ 토대의 뇌졸중의 위험 환자 및 원인 진단
ES2899923T3 (es) * 2011-12-01 2022-03-15 Hoffmann La Roche NT-proANP y NT-proBNP para el diagnóstico de apoplejía
GB2497138A (en) * 2011-12-02 2013-06-05 Randox Lab Ltd Biomarkers for stroke and stroke subtype diagnosis.
CA2897327A1 (en) * 2013-01-08 2014-07-17 Sphingotec Gmbh Fasting levels of growth hormone as a predictive marker of cardiovascular risk
US20150302155A1 (en) * 2014-04-16 2015-10-22 Xerox Corporation Methods and systems for predicting health condition of human subject
US10172568B2 (en) * 2014-07-14 2019-01-08 Medtronic, Inc. Determining prospective risk of heart failure hospitalization
CN111624346A (zh) 2014-08-14 2020-09-04 米密德诊断学有限公司 用于预测及/或决定预后的套组
EP3201631B1 (en) * 2014-10-01 2021-05-26 SphingoTec GmbH Hgh determination for use to guide prevention of a major adverse cardiac event or a cardiovascular disease in a subject
WO2017149548A1 (en) 2016-03-03 2017-09-08 Memed Diagnostics Ltd. Rna determinants for distinguishing between bacterial and viral infections
US11353456B2 (en) * 2016-09-29 2022-06-07 Memed Diagnostics Ltd. Methods of risk assessment and disease classification for appendicitis
JP6933033B2 (ja) * 2017-07-31 2021-09-08 ブラザー工業株式会社 画像形成装置
CN108761092A (zh) * 2018-07-18 2018-11-06 长春恒晓生物科技有限责任公司 建立时间分辨荧光免疫层析法检测和肽素试剂盒
CN109975532A (zh) * 2019-03-21 2019-07-05 王鑫 缺血性卒中人群康复治疗的预后评估
CN110797120A (zh) * 2019-10-23 2020-02-14 苏州大学 整合表观遗传因素的缺血性脑卒中不良结局风险预测装置
KR102362951B1 (ko) * 2020-08-13 2022-02-14 연세대학교 원주산학협력단 프로칼시토닌 대 ｃ­반응성 단백질의 비율을 이용한 허혈성 뇌졸중의 단기 사망률 예측 방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7713705B2 (en) * 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
ATE445160T1 (de) * 2001-08-20 2009-10-15 Biosite Inc Diagnostische marker für schlaganfall und hirntrauma sowie verfahren zur verwendung davon
JP2006526140A (ja) * 2002-12-24 2006-11-16 バイオサイト インコーポレイテッド 鑑別診断のためのマーカーおよびその使用方法
ZA200401646B (en) * 2003-03-12 2004-06-07 Reliance Life Sciences Pvt Ltd Derivation of terminally differentiated dopaminergic neurons from human embryonic stem cells.
US20090035287A1 (en) * 2005-09-26 2009-02-05 Zurit Levine Atrial natriuretic peptide (anp) splice variants and methods of using same
CN101096705A (zh) * 2006-06-27 2008-01-02 安徽省生物医学研究所 多态性位点基因型预测心脑血管疾病发生及预后的用途、方法和试剂盒
ES2652027T3 (es) * 2006-10-26 2018-01-31 B.R.A.H.M.S. Gmbh Estratificación de riesgo del síndrome coronario agudo por medio de fragmentos / péptidos parciales de la provasopresina, en particular copeptina o neurofisina II
US9012151B2 (en) * 2006-11-09 2015-04-21 B.R.A.H.M.S. Gmbh Methods of diagnosis and risk stratification of adverse events in post myocardial infarction patients using pro-adrenomedullin
ES2724478T3 (es) 2008-10-24 2019-09-11 Brahms Gmbh Pronóstico y evaluación del riesgo en pacientes con accidente cerebrovascular determinando el nivel de péptidos marcadores

Also Published As

Publication number Publication date
JP5902479B2 (ja) 2016-04-13
ES2724478T3 (es) 2019-09-11
CN102257386A (zh) 2011-11-23
JP2012506545A (ja) 2012-03-15
US10067063B2 (en) 2018-09-04
EP2356450B1 (en) 2019-02-06
US20110263821A1 (en) 2011-10-27
JP2016029394A (ja) 2016-03-03
EP2356450A1 (en) 2011-08-17
US20140017808A1 (en) 2014-01-16
WO2010046136A1 (en) 2010-04-29
CN102257386B (zh) 2014-12-31

Similar Documents

Publication Publication Date Title
HK1162665A1 (en) Prognosis and risk assessment in patients having suffered a stroke or a transient ischemic attack by determining the level of marker peptides
EP2252703A4 (en) DISEASE MARKERS AND USES THEREOF
EP2254463A4 (en) DEVICE AND METHOD FOR PHOTOGRAMMICALLY BASED MYOCARDIAL MATCHING
GB0705187D0 (en) Improvements in or relating to level measurement
BRPI1015334A2 (pt) "medição de carga com base na pressão"
GB2459471B (en) Forecasting asphaltic precipitation
IL211930A (en) Peptides and nonsense for their use in preventing cell adhesion
BRPI0920377A2 (pt) âncora com acoplamento de medição
GB0903943D0 (en) Liquid electrolyte compositions and its use in gas sensors
DE602008001148D1 (de) Messinstrument
GB0821250D0 (en) Displacement measurement arrangement and method
GB0822283D0 (en) Improvements in or relating to level sensors
GB2477240B (en) Sacrificial anodes in concrete patch repair
GB201107182D0 (en) Improvements in or relating to sensing arrangements
ZA201104160B (en) Crhr2 peptide agonists and uses thereof
GB0804149D0 (en) A wear indicator for a sacrificial anode and a sacrificial anode comprising the same
GB2452144B (en) Indication position calculation mark unit
EP2408911A4 (en) EXPRESSION OF POLYPEPTIDES IN CILIATES
GB0805364D0 (en) Object and group marker display
TWM387507U (en) Foot bottom curvature measuring device and its system
DK2358585T3 (da) Forbedring i eller i forbindelse med flydeanordninger
GB0701198D0 (en) In-cylinder pressure measurement system
GB2472237B (en) Improvements in or relating to level measurement
FI20080301A0 (fi) Tasomainen anturirakenne
GB0611867D0 (en) Brick gauge marker